CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 1,900 shares, a drop of 60.4% from the February 28th total of 4,800 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 9,500 shares, the short-interest ratio is currently 0.2 days.

CollPlant Biotechnologies Stock Performance

Shares of CollPlant Biotechnologies stock traded down $0.07 during trading on Friday, hitting $2.63. 3,279 shares of the company’s stock were exchanged, compared to its average volume of 10,561. The stock has a market capitalization of $30.13 million, a price-to-earnings ratio of -1.71 and a beta of 1.07. The business has a 50-day simple moving average of $3.47 and a 200-day simple moving average of $3.95. CollPlant Biotechnologies has a 52-week low of $2.56 and a 52-week high of $6.75.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.36 million. CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. On average, equities analysts anticipate that CollPlant Biotechnologies will post -1.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CollPlant Biotechnologies

Hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN increased its stake in shares of CollPlant Biotechnologies by 110.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after purchasing an additional 4,405 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in CollPlant Biotechnologies in the 4th quarter valued at about $38,000. Benjamin Edwards Inc. purchased a new position in CollPlant Biotechnologies in the 3rd quarter worth approximately $112,000. Finally, AMH Equity Ltd boosted its holdings in shares of CollPlant Biotechnologies by 17.4% during the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after purchasing an additional 17,295 shares during the last quarter. 21.69% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CLGN has been the topic of several research analyst reports. D. Boral Capital reiterated a “buy” rating and set a $14.00 price target on shares of CollPlant Biotechnologies in a research note on Thursday. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a research report on Friday, November 29th.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.